Andrx Receives First Generic Approval For Abbott's Biaxin XL
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic firm does not plan to market clarithromycin extended-release 500 mg tablets until expiration of Abbott's compound patent in May 2005. Abbott says the XL formulation is patented through 2017.
You may also be interested in...
Abbott To Assert New Biaxin XL Patent In Ongoing Suits
Abbott is asserting its new pharmacokinetic patent issued for Biaxin XL (clarithromycin extended-release) in ongoing litigation, the company said during its earnings call April 12
Abbott To Assert New Biaxin XL Patent In Ongoing Suits
Abbott is asserting its new pharmacokinetic patent issued for Biaxin XL (clarithromycin extended-release) in ongoing litigation, the company said during its earnings call April 12
Abbott To Bolster Biaxin XL Patent Protection Ahead Of Compound Expiration In May
The additional intellectual property for the extended-release formulation will give generic firms “something to think about,” Abbott CFO Freyman says at SG Cowen investor conference. Abbott says it filed suit against three generic manufacturers March 14.